| 2018-06 |
The effect of best response to prior anticancer therapy on efficacy outcomes in the napoli-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy |
Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-152. |
 |
| 2018-06 |
Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC) |
Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-153. |
|
| 2018-06 |
Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC) |
Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-150. |
|
| 2018-06 |
Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial |
Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract O-004. |
|
| 2018-06 |
Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial |
Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-151. |
|
| 2018-05 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials |
Journal of Clinical Oncology. 2018 May;36(15, Suppl.):Abstract number e15127. |
|
| 2018-05 |
A phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers |
Journal of Clinical Oncology. 2018 May;36(15, Suppl. S):Meeting Abstract 2556. |
|
| 2018-05 |
A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy |
Journal of Clinical Oncology. 2018 May;36(15, Suppl.):Meeting Abstract e16204. |
|
| 2018-02 |
Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pan |
Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 460. |
|
| 2018-02 |
Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) +/- 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1. |
Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 459. |
|
| 2018-02 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials |
Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 90. |
|
| 2018-02 |
Dose modifications of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy |
Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):388. |
|
| 2018-02 |
Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) p |
Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):379. |
|
| 2018-02 |
Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)+/--5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with g |
Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):410. |
|
| 2018-01 |
Role of academic institute in cancer therapy development in National Institute of Cancer Research, NHRI in Taiwan |
Cancer Science. 2018 Jan;109(Suppl. 1):43. |
|
| 2018-01 |
Environmental tobacco smoke and risk of pancreatic cancer among never smokers |
Cancer Science. 2018 Jan;109(Suppl. 1):769. |
|
| 2018-01 |
The role of aberrant mitochondrial phosphoenolpyruvate carboxykinase expression in pancreatic neuroendocrine tumors |
Cancer Science. 2018 Jan;109(Suppl. 1):466. |
|
| 2017-11 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI65-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy |
Annals of Oncology. 2017 Nov;28(Suppl. 10):67-U261. |
|
| 2017-11 |
CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) � 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy |
Annals of Oncology. 2017 Nov;28(Suppl. 10):Meeting Abstract 227P. |
|
| 2017-09 |
ATTRACTION-04 (ONO-4538-37): A randomized, multicenter, phase 2/3 study of nivolumab (Nivo) plus chemotherapy in patients (Pts) with previously untreated advanced or recurrent gastric (G) or gastroesophageal junction (GEJ) cancer |
Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 777TiP. |
|
| 2017-09 |
ATTRACTION-05 (ONO-4538-38/BMS CA209844): A randomized, multicenter, double-blind, placebo-controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer |
Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 778TiP. |
|
| 2017-09 |
Inhibition of the ubiquitin-conjugating enzyme E2B restores the BCNU sensitivity of cancer cells by regulating MGMT ubiquitination |
Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 55P. |
|
| 2017-09 |
Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alon |
Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 741P. |
|
| 2017-09 |
Mutant KIT translocates into the nucleus and induces NFKBIB expression that leads to KIT expression in imatinib-resistant gastrointestinal stromal tumors |
Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 1679P. |
|
| 2017-09 |
Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37) |
Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 671P. |
|
| 2017-09 |
A Phase 3 Study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Updated results and subset analysis by PD-L1 expression (ATTRACTION-02) |
Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 617O. |
|
| 2017-06-26 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI +/- 5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy |
Annals of Oncology. 2017 Jun 26;28(Suppl. 3):Abstract number PD - 018. |
|
| 2017-06-26 |
CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) +/- 5-fluorouracil and leucovorin (5FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy |
Annals of Oncology. 2017 Jun 26;28(Suppl. 3):Abstract number PD-017. |
|
| 2017-05 |
The prognostic value of baseline neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM |
Journal of Clinical Oncology. 2017 May;35:Meeting Abstract e15795. |
|
| 2017-02 |
Efficacy and safety of liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPO |
Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):303. |
|
| 2017-02 |
A phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer |
Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):417. |
|
| 2017-02 |
Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial |
Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):2. |
|
| 2017-02 |
Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-FU/LV |
Journal of Clinical Oncology. 2017 Feb;35(4):Meeting Abstract 293. |
|
| 2016-12 |
Efficacy and safety of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02, BAX-2398) in patients with metastatic pancreatic cancer in Asia: A subgroup analysis of the phase 3 NAPOLI-1 Study |
Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 221PD. |
|
| 2016-12 |
Effects of nal-IRI (MM-398) +/- 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1 |
Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 242P. |
|
| 2016-12 |
Sequential use of everolimus and sunitinib in treating WHO grade 1 and 2 pancreatic neuroendocrine tumors-retrospective multi-center study in Taiwan |
Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 420P. |
|
| 2016-11 |
Role of epigenetic regulator EHMT2 in the regulation of gemcitabine resistance in pancreatic cancer |
Journal of Gastroenterology and Hepatology. 2016 Nov;31(Suppl. 3):245. |
|
| 2016-10 |
Effects of nanoliposomal irinotecan (nal-IRI;MM-398) +/- 5-Fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-b |
Oncology Research and Treatment. 2016 Oct;39(Suppl. 3):259. |
|
| 2016-10 |
Quality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with ge |
Oncology Research and Treatment. 2016 Oct;39(Suppl. 3):260. |
|
| 2016-10 |
Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy |
Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 622PD. |
|
| 2016-10 |
Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther |
Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 693P. |
|
| 2016-10 |
CagA and NFAT co-operatively participate in the lymphomagenesis of gastric MALT lymphoma |
Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 933P. |
|
| 2016-09 |
Effects of nanoliposomal irinotecan (nal-IRI; MM-398) +/- 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: Results from t |
Annals of Oncology. 2016 Sep;27(Suppl. 4):Meeting Abstract B04. |
|
| 2016-06 |
Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): A randomized, open-label phase 2 study |
Annals of Oncology. 2016 Jun;27(Suppl. 2):ii84. |
|
| 2016-06 |
Effects of nal-IRI (MM-398) +/- 5-fluorouracil on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine |
Annals of Oncology. 2016 Jun;27(Suppl. 2):119. |
|
| 2016-06 |
Safety across subgroups in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy |
Annals of Oncology. 2016 Jun;27(Suppl. 2):110. |
|
| 2016-05 |
Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine |
Journal of Clinical Oncology. 2016 May;34(15, Suppl.):Meeting Abstract 4126. |
|
| 2016-05 |
Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1: A randomized phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy |
Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e15740. |
|
| 2016-05 |
Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC) |
Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number 4017. |
|
| 2016-05 |
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with |
Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e15732. |
|
